Scarica l'app Stockscreener
14.17
2.68%
-0.39
Pre-mercato:
14.13
-0.04
-0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Avoiding Lag: Real-Time Signals in (OCUL) Movement - news.stocktradersdaily.com
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission - Investing.com
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Sahm
Why Is Ocular Therapeutix Stock Skyrocketing Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Paramount Skydance, Wave Life Sciences, Ocular… - inkl
Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC - MarketBeat
OCUL: Needham Reiterates Buy Rating with $20 Price Target | OCUL Stock News - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's Why - MarketBeat
Ocular Therapeutix stock price target raised to $28 from $19 at Raymond James - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD - Investing.com
Ocular Therapeutix Inc.’s Breakthrough: Will It Spark a Surge? - timothysykes.com
OCUL's Target Price Raised to $21 by HC Wainwright & Co. | OCUL Stock News - GuruFocus
Ocular Therapeutix (OCUL) Plans NDA Submission for Wet AMD Treat - GuruFocus
H.C. Wainwright raises Ocular Therapeutix stock price target to $21 on FDA pathway - Investing.com UK
Ocular Therapeutix says SOL-1 topline data expected in first quarter 2026 - marketscreener.com
Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug - TradingView — Track All Markets
Ocular Therapeutix Plans NDA Submission for AXPAXLI in Wet AMD Following Positive SOL-1 Year One Data - Quiver Quantitative
Ocular Therapeutix, Inc. Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix, Inc. $OCUL Position Boosted by Pale Fire Capital SE - MarketBeat
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
AXPAXLI NDA Acceleration Might Change The Case For Investing In Ocular Therapeutix (OCUL) - Sahm
Ocular Therapeutix reports inducement grant under NASDAQ listing rule - MSN
Ocular Therapeutix (OCUL): Is the Recent Share Price Momentum Backed by Its Valuation? - Sahm
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges - ts2.tech
Ocular Therapeutix plans new drug application for AXPAXLI based on Phase 3 data - Investing.com Nigeria
Ocular Therapeutix Plans NDA Submission for Wet AMD Treatment - TradingView — Track All Markets
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 12.3%What's Next? - MarketBeat
With Ocular Therapeutix Stock Surging, Have You Considered The Downside? - Trefis
Ocular Therapeutix reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Saturn V Capital Management LP Purchases 130,385 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What sentiment indicators say about Ocular Therapeutix Inc. stockWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
How Ocular Therapeutix Inc. stock reacts to inflationary pressuresDollar Strength & Reliable Breakout Forecasts - Newser
How forex fluctuations impact Ocular Therapeutix Inc. (0OT) stockJuly 2025 PostEarnings & Weekly Top Gainers Trade List - Newser
OCUL: Phase III trials target a first-in-class superiority label and durable retinal disease therapy - TradingView
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):